Connors Investor Services Inc. boosted its position in shares of Eli Lilly and Company (NYSE:LLY) by 3.4% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 58,078 shares of the company’s stock after purchasing an additional 1,910 shares during the period. Connors Investor Services Inc.’s holdings in Eli Lilly and were worth $4,780,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in LLY. Pathstone Family Office LLC lifted its position in shares of Eli Lilly and by 100.0% in the second quarter. Pathstone Family Office LLC now owns 58 shares of the company’s stock worth $4,774,000 after buying an additional 29 shares during the last quarter. Vantage Financial Partners Ltd. Inc. acquired a new stake in shares of Eli Lilly and in the second quarter worth about $494,000. Acrospire Investment Management LLC lifted its position in shares of Eli Lilly and by 16.7% in the second quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock worth $115,000 after buying an additional 200 shares during the last quarter. Point72 Asia Hong Kong Ltd lifted its position in shares of Eli Lilly and by 237.4% in the first quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock worth $148,000 after buying an additional 1,239 shares during the last quarter. Finally, Shine Investment Advisory Services Inc. acquired a new stake in shares of Eli Lilly and in the second quarter worth about $148,000. 75.48% of the stock is owned by hedge funds and other institutional investors.
LLY has been the subject of a number of analyst reports. Zacks Investment Research raised Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 price target for the company in a research report on Monday, July 17th. Deutsche Bank AG reaffirmed a “buy” rating and issued a $91.00 price target (up previously from $90.00) on shares of Eli Lilly and in a research report on Monday, July 17th. Leerink Swann cut Eli Lilly and from an “outperform” rating to a “market perform” rating and reduced their price target for the stock from $93.00 to $90.00 in a research report on Wednesday, July 26th. BMO Capital Markets reaffirmed an “underperform” rating and issued a $73.00 price target on shares of Eli Lilly and in a research report on Wednesday, July 26th. Finally, Oppenheimer Holdings, Inc. cut Eli Lilly and from an “outperform” rating to a “market perform” rating and set a $90.00 price target for the company. in a research report on Wednesday, July 26th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and ten have given a buy rating to the company’s stock. Eli Lilly and presently has a consensus rating of “Hold” and an average target price of $89.76.
TRADEMARK VIOLATION WARNING: This article was originally published by Markets Daily and is the sole property of of Markets Daily. If you are reading this article on another website, it was stolen and republished in violation of United States & international copyright law. The legal version of this article can be read at https://www.themarketsdaily.com/2017/11/14/connors-investor-services-inc-grows-position-in-eli-lilly-and-company-lly.html.
Eli Lilly and Company (NYSE:LLY) opened at $82.86 on Tuesday. Eli Lilly and Company has a 12 month low of $64.18 and a 12 month high of $89.09. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.03 and a current ratio of 1.38. The stock has a market capitalization of $91,710.21, a PE ratio of 20.36, a P/E/G ratio of 1.83 and a beta of 0.34.
Eli Lilly and (NYSE:LLY) last issued its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.03 by $0.02. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The firm had revenue of $5.66 billion for the quarter, compared to analyst estimates of $5.52 billion. During the same period in the previous year, the company posted $0.88 earnings per share. The company’s quarterly revenue was up 9.0% compared to the same quarter last year. equities analysts anticipate that Eli Lilly and Company will post 4.22 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 8th. Stockholders of record on Wednesday, November 15th will be paid a $0.52 dividend. The ex-dividend date of this dividend is Tuesday, November 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.51%. Eli Lilly and’s dividend payout ratio is currently 98.58%.
In other news, SVP Alfonso G. Zulueta sold 2,003 shares of the company’s stock in a transaction that occurred on Friday, November 10th. The stock was sold at an average price of $83.67, for a total value of $167,591.01. Following the sale, the senior vice president now directly owns 43,580 shares in the company, valued at approximately $3,646,338.60. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, major shareholder Lilly Endowment Inc sold 205,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 4th. The shares were sold at an average price of $86.81, for a total value of $17,796,050.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 772,003 shares of company stock worth $64,837,441. Corporate insiders own 0.20% of the company’s stock.
Eli Lilly and Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.